1. Generics Bulletin
  2. >>Products
  3. >>Generics

Ranitidine Recalls Begin As European Regulators Take Action

 
• By Tom Gallen

OTC ranitidine products are among the first to be recalled in Europe following the discovery of a human carcinogen in ranitidine-based drugs.With investigations underway worldwide, regulators across Europe are split into two camps: immediate action or wait and see.

Recall
Ranitidine recalls have begun across Europe • Source: Shutterstock

Germany, Switzerland and Austria are the first European countries to initiate recalls of ranitidine-based drugs after tests showed that certain products contained N-nitrosodimethylamine, a probable human carcinogen.

With a Europe-wide review of ranitidine underway at the European Medicines Agency, national regulators in the DACH region are overseeing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 
• By Michael McCaughan

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Generic Entresto Floods US Market Following MSN Patent Victory

 
• By Dean Rudge

As many as ten generic versions of Novartis’ blockbuster heart failure drug Entresto (sacubitril/valsartan) have begun entering the US market following recent key legal victories by MSN Laboratories.

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.

More from Products

Generic Entresto Floods US Market Following MSN Patent Victory

 
• By Dean Rudge

As many as ten generic versions of Novartis’ blockbuster heart failure drug Entresto (sacubitril/valsartan) have begun entering the US market following recent key legal victories by MSN Laboratories.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By Dave Wallace

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.

Sandoz Streamlines More Trials As First-Half Biosimilars Sales Hit $1.5bn

 
• By Dave Wallace

Sandoz has revealed plans to streamline more biosimilar trials amid evolving regulatory moves towards minimizing the need for comparative efficacy studies. The disclosure was just one of many pipeline and portfolio updates provided as the firm delivered positive first-half results.